Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron (REGN) reported $3.79 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.3%. EPS of $12.07 for the same period compares to $11.86 a year ago ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

Trevogrumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success ...